The Role of Guidelines on Molecular Testing in Ovarian Cancer

Video content above is prompted by the following:

NCCN Guideline Updates on Molecular Testing

BRCA testing serves 3 critical functions in ovarian cancer management:

• Informs treatment decisions, particularly for PARP inhibitor therapy
• Provides prognostic information (BRCA mutations indicate better response to platinum-based chemotherapy)
• Identifies hereditary risk to enable family testing and risk-reducing surgeries

The comprehensive approach to biomarker testing has shifted from “à la carte” testing to more integrated panel testing performed at diagnosis. This ensures clinicians are prepared with complete molecular information when making treatment decisions.